Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06454669 · ClinicalTrials.gov registry record · Phase 2

Dronabinol as an Adjunct for Reducing Pain

A Phase 2 study of Chronic Pain and Low Back Pain, sponsored by Christopher D. Verri.

Recruiting
Registry status
Phase 2
Development phase
75
Enrollment target
1
Study location

NCT06454669: Recruiting Phase 2 study of Chronic Pain and Low Back Pain, sponsored by Christopher D. Verri.

NCT06454669 is a Phase 2 study of Chronic Pain and Low Back Pain that is actively recruiting participants, run by Christopher D. Verri. The registered enrollment target is 75 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06454669, a Phase 2 study of Chronic Pain and Low Back Pain, is actively recruiting participants, sponsored by Christopher D. Verri.

RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for chronic low back pain (cLBP) with a 2:1 allocation ratio. Up to 75 subjects will be enrolled in this pilot study and randomized to receive doses of THC (up to 30 mg/day), orally, over 8 weeks. This study will be conducted at a single site; it does not include any stratifications, and there is no interim analysis planned. Notably, the goal is to determine whether there is enough evidence of the safety of THC to support the development of later-phase clinical trials. Thus, detailed developmental plans are contingent on the outcomes of this study.

Primary Outcome

For change in pain intensity from baseline to 8-weeks, the investigators will estimate the mean within each arm using the Research Standards for Chronic Low-Back Pain (RScLBP).

Interventions

  • DRUG Placebo
  • DRUG Dronabinol

Study Locations (1)

Texas

  • Michael E Debakey VA Medical Center - Houston

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2024-06-15
Est. Completion 2029-12-31
Phase Phase 2
Christopher D. Verri

1 total trials

What NCT06454669 shows while recruiting

NCT06454669 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (90% lower).

The record links to 3 conditions, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06454669 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06454669 about?

NCT06454669 is a clinical study titled "Dronabinol as an Adjunct for Reducing Pain". This exploratory, proof-of-concept study is a double-blind (participants and investigators will be blinded), placebo-controlled, randomized, two-arm clinical trial of Marinol \[dronabinol, synthetic Δ9-tetrahydrocannabinol (THC)\] for chronic low back pain (cLBP) with a 2:1 allocation ratio. Up to 7...

What is the current status of trial NCT06454669?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2024-06-15. Estimated completion is 2029-12-31.

What conditions does trial NCT06454669 study?

This clinical trial studies the following conditions: Chronic Pain, Low Back Pain, Back Injuries.

What interventions are being tested in trial NCT06454669?

The interventions under investigation include: Placebo (DRUG), Dronabinol (DRUG).

Who is sponsoring clinical trial NCT06454669?

This trial is sponsored by Christopher D. Verri, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06454669 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06454669's enrollment target sits among peer trials

75 159th of 301 higher than 140 of 301 other Chronic Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06454669, the US trial registry maintained by the National Library of Medicine. NCT06454669 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.